Drug Development

Gene Therapy Restores Sight in a Pediatric Patient with DEB

August 9, 2023 - Alfonso Sabater, MD, PhD, played a significant role in restoring the vision of 14-year-old Antonio Vento, a dystrophic epidermolysis bullosa (DEB) patient. Alongside two surgical procedures, a recently approved topical gene therapy, VYJUVEK, assisted in recovering the patient’s sight. DEB is a genetic condition that weakens a patient’s...

Read More


More Articles

Viatris Closes Acquisitions of Oyster Point Pharma and Famy Life Sciences

by Hayden Schmidt

At the beginning of this month, global healthcare firm Viatris Inc announced the completion of its Oyster Point Pharma and Famy Life Sciences acquisitions. The two companies will be combined, and...

Thermo Fisher Introduces System to Enable Cell Therapy Development

by Samantha McGrail

Thermo Fisher Scientific recently introduced a new large-volume electroporation system that allows cell therapy developers to quickly move from clinical development to commercial...

Recent Articles